FR3015483B1 - Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent - Google Patents

Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Info

Publication number
FR3015483B1
FR3015483B1 FR1363500A FR1363500A FR3015483B1 FR 3015483 B1 FR3015483 B1 FR 3015483B1 FR 1363500 A FR1363500 A FR 1363500A FR 1363500 A FR1363500 A FR 1363500A FR 3015483 B1 FR3015483 B1 FR 3015483B1
Authority
FR
France
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
containing same
thienopyrimidine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1363500A
Other languages
English (en)
Other versions
FR3015483A1 (fr
Inventor
Andras Kotschy
Zoltan Szlavik
Marton Csekei
Attila Paczal
Zoltan Szabo
Szabolcs Sipos
Gabor Radics
Agnes Proszenyak
Balazs Balint
Alain Bruno
Olivier Geneste
James Edward Paul Davidson
James Brooke Murray
I-Jen Chen
Sierra Francoise Perron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Vernalis R&D Ltd
Original Assignee
Laboratoires Servier SAS
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS, Vernalis R&D Ltd filed Critical Laboratoires Servier SAS
Priority to FR1363500A priority Critical patent/FR3015483B1/fr
Priority to JOP/2014/0353A priority patent/JO3193B1/ar
Priority to IL236143A priority patent/IL236143A/en
Priority to CR20140569A priority patent/CR20140569A/es
Priority to PH12014000375A priority patent/PH12014000375B1/en
Priority to NZ702851A priority patent/NZ702851B/en
Priority to TN2014000516A priority patent/TN2014000516A1/fr
Priority to CA2875226A priority patent/CA2875226C/fr
Priority to AU2014274644A priority patent/AU2014274644B2/en
Priority to AP2014008127A priority patent/AP2014008127A0/xx
Priority to PE2014002444A priority patent/PE20151064A1/es
Priority to DO2014000282A priority patent/DOP2014000282A/es
Priority to CUP2014000143A priority patent/CU24309B1/xx
Priority to MX2014015854A priority patent/MX351581B/es
Priority to ZA2014/09365A priority patent/ZA201409365B/en
Priority to CL2014003444A priority patent/CL2014003444A1/es
Priority to MYPI2014703853A priority patent/MY185221A/en
Priority to NI201400150A priority patent/NI201400150A/es
Priority to CN201410800069.2A priority patent/CN104725397B/zh
Priority to US14/576,683 priority patent/US9670227B2/en
Priority to JP2014257658A priority patent/JP5922215B2/ja
Priority to GEAP201413667A priority patent/GEP201706619B/en
Priority to UAA201413661A priority patent/UA120341C2/uk
Priority to LTEP14199533.2T priority patent/LT2886545T/lt
Priority to EA201401292A priority patent/EA029601B1/ru
Priority to TW103144845A priority patent/TWI508969B/zh
Priority to SG10201408563UA priority patent/SG10201408563UA/en
Priority to PL14199533T priority patent/PL2886545T3/pl
Priority to SA114360144A priority patent/SA114360144B1/ar
Priority to BR102014032336-8A priority patent/BR102014032336B1/pt
Priority to MEP-2016-207A priority patent/ME02521B/fr
Priority to MDA20140137A priority patent/MD4516C1/ro
Priority to RS20160802A priority patent/RS55213B1/sr
Priority to ES14199533.2T priority patent/ES2594377T3/es
Priority to ARP140104847A priority patent/AR098906A1/es
Priority to GT201400297A priority patent/GT201400297A/es
Priority to PCT/EP2014/078947 priority patent/WO2015097123A1/fr
Priority to RU2014151850/04A priority patent/RU2605403C2/ru
Priority to HUE14199533A priority patent/HUE029654T2/en
Priority to PT141995332T priority patent/PT2886545T/pt
Priority to EP14199533.2A priority patent/EP2886545B1/fr
Priority to UY0001035915A priority patent/UY35915A/es
Priority to SI201430061A priority patent/SI2886545T1/sl
Priority to DK14199533.2T priority patent/DK2886545T3/en
Priority to KR1020140187349A priority patent/KR101636401B1/ko
Priority to CO14282098A priority patent/CO7210068A1/es
Publication of FR3015483A1 publication Critical patent/FR3015483A1/fr
Priority to HK15110667.4A priority patent/HK1209750A1/xx
Priority to HK15112389.7A priority patent/HK1211583A1/xx
Application granted granted Critical
Publication of FR3015483B1 publication Critical patent/FR3015483B1/fr
Priority to HRP20161203TT priority patent/HRP20161203T8/hr
Priority to CY20161100949T priority patent/CY1118058T1/el
Priority to US15/492,306 priority patent/US10278972B2/en
Priority to US16/296,766 priority patent/US20190201404A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
FR1363500A 2013-12-23 2013-12-23 Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Expired - Fee Related FR3015483B1 (fr)

Priority Applications (52)

Application Number Priority Date Filing Date Title
FR1363500A FR3015483B1 (fr) 2013-12-23 2013-12-23 Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JOP/2014/0353A JO3193B1 (ar) 2013-12-23 2014-12-08 مشتقات ثينوبيريميدين جديدة وعملية لتحضيرها والتركيبات الدوائية التي تحتوي عليها
IL236143A IL236143A (en) 2013-12-23 2014-12-09 History of theonfirmidine, a process for their preparation and their pharmaceutical preparations
CR20140569A CR20140569A (es) 2013-12-23 2014-12-10 Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contiene
PH12014000375A PH12014000375B1 (en) 2013-12-23 2014-12-10 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
NZ702851A NZ702851B (en) 2013-12-23 2014-12-10 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2014000516A TN2014000516A1 (en) 2013-12-23 2014-12-11 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
CA2875226A CA2875226C (fr) 2013-12-23 2014-12-11 Derives de thienopyrimidine, procede de preparation desdits derives, compositions pharmaceutiques en renfermant et leur utilisation pour le traitement de troubles associes a une defaillance d'apoptose
AU2014274644A AU2014274644B2 (en) 2013-12-23 2014-12-12 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
AP2014008127A AP2014008127A0 (en) 2013-12-23 2014-12-12 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
PE2014002444A PE20151064A1 (es) 2013-12-23 2014-12-15 Nuevos derivados tienopirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen
DO2014000282A DOP2014000282A (es) 2013-12-23 2014-12-15 Nuevos derivados tienopirimidina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen
CUP2014000143A CU24309B1 (es) 2013-12-23 2014-12-17 Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen
MX2014015854A MX351581B (es) 2013-12-23 2014-12-18 Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
ZA2014/09365A ZA201409365B (en) 2013-12-23 2014-12-18 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
CL2014003444A CL2014003444A1 (es) 2013-12-23 2014-12-18 Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
MYPI2014703853A MY185221A (en) 2013-12-23 2014-12-18 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
NI201400150A NI201400150A (es) 2013-12-23 2014-12-19 Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CN201410800069.2A CN104725397B (zh) 2013-12-23 2014-12-19 噻吩并嘧啶衍生物、其制备方法以及含有它们的药用组合物
US14/576,683 US9670227B2 (en) 2013-12-23 2014-12-19 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
JP2014257658A JP5922215B2 (ja) 2013-12-23 2014-12-19 新規なチエノピリミジン誘導体、その製造方法及びそれを含有する医薬組成物
GEAP201413667A GEP201706619B (en) 2013-12-23 2014-12-19 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical composition containing them
UAA201413661A UA120341C2 (uk) 2013-12-23 2014-12-19 Похідні тієнопіримідину, спосіб їх отримання і фармацевтичні композиції, що їх містять
LTEP14199533.2T LT2886545T (lt) 2013-12-23 2014-12-22 Nauji tienopirimidino dariniai, jų gamybos būdas ir juos turinčios farmacinės kompozicijos
EA201401292A EA029601B1 (ru) 2013-12-23 2014-12-22 Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
TW103144845A TWI508969B (zh) 2013-12-23 2014-12-22 新噻吩并嘧啶衍生物、其製備方法及包含其之醫藥組合物
SG10201408563UA SG10201408563UA (en) 2013-12-23 2014-12-22 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
PL14199533T PL2886545T3 (pl) 2013-12-23 2014-12-22 Nowe pochodne tienopirymidyn, sposób ich wytwarzania, oraz zawierające je kompozycje farmaceutyczne
SA114360144A SA114360144B1 (ar) 2013-12-23 2014-12-22 مشتقات ثينوبيريميدين جديدة، عملية لتحضيرها وتركيبات دوائية تحتويها
BR102014032336-8A BR102014032336B1 (pt) 2013-12-23 2014-12-22 compostos derivados de tienopirimidina, seus processos de preparação, composições farmacêuticas e seus usos
MEP-2016-207A ME02521B (fr) 2013-12-23 2014-12-22 Nouveaux dérivés de thiénopyrimidine, leur procédé de préparation et compositions pharmaceutiques les contenant
MDA20140137A MD4516C1 (ro) 2013-12-23 2014-12-22 Derivaţi noi de tienopirimidină, procedeu de preparare a acestora, compoziţii farmaceutice care îi conţin şi utilizările lor în calitate de agenţi proapoptotici
RS20160802A RS55213B1 (sr) 2013-12-23 2014-12-22 Novi derivati tienopirimidina, postupak njihove izrade i farmaceutske smeše koje ih sadrže
ES14199533.2T ES2594377T3 (es) 2013-12-23 2014-12-22 Nuevos derivados de tienopirimidina, procedimiento para su preparación y composiciones farmacéuticas que los contienen
ARP140104847A AR098906A1 (es) 2013-12-23 2014-12-22 Derivados de tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
GT201400297A GT201400297A (es) 2013-12-23 2014-12-22 Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
PCT/EP2014/078947 WO2015097123A1 (fr) 2013-12-23 2014-12-22 Nouveaux dérivés de thiénopyrimidine, procédé pour leur préparation et compositions pharmaceutiques les contenant
RU2014151850/04A RU2605403C2 (ru) 2013-12-23 2014-12-22 Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
HUE14199533A HUE029654T2 (en) 2013-12-23 2014-12-22 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
PT141995332T PT2886545T (pt) 2013-12-23 2014-12-22 Novos derivados de tienopirimidina, um processo para a sua preparação e composições farmacêuticas que os contêm
EP14199533.2A EP2886545B1 (fr) 2013-12-23 2014-12-22 Nouveaux dérivés de thiénopyrimidine, leur procédé de préparation et compositions pharmaceutiques les contenant
UY0001035915A UY35915A (es) 2013-12-23 2014-12-22 Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
SI201430061A SI2886545T1 (sl) 2013-12-23 2014-12-22 Novi derivati tienopirimidina, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
DK14199533.2T DK2886545T3 (en) 2013-12-23 2014-12-22 Thienopyrimidinderivater new, a process for their preparation and pharmaceutical compositions containing them
KR1020140187349A KR101636401B1 (ko) 2013-12-23 2014-12-23 티에노피리미딘 유도체, 이의 제조 방법 및 이를 함유하는 약제학적 조성물
CO14282098A CO7210068A1 (es) 2013-12-23 2014-12-23 Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
HK15110667.4A HK1209750A1 (en) 2013-12-23 2015-10-28 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
HK15112389.7A HK1211583A1 (en) 2013-12-23 2015-12-16 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
HRP20161203TT HRP20161203T8 (hr) 2013-12-23 2016-09-20 Novi derivati tienopirimidina, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže
CY20161100949T CY1118058T1 (el) 2013-12-23 2016-09-22 Νεα παραγωγα θειενοπυριμιδινης, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
US15/492,306 US10278972B2 (en) 2013-12-23 2017-04-20 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
US16/296,766 US20190201404A1 (en) 2013-12-23 2019-03-08 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1363500A FR3015483B1 (fr) 2013-12-23 2013-12-23 Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
FR3015483A1 FR3015483A1 (fr) 2015-06-26
FR3015483B1 true FR3015483B1 (fr) 2016-01-01

Family

ID=50829005

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1363500A Expired - Fee Related FR3015483B1 (fr) 2013-12-23 2013-12-23 Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Country Status (48)

Country Link
US (3) US9670227B2 (fr)
EP (1) EP2886545B1 (fr)
JP (1) JP5922215B2 (fr)
KR (1) KR101636401B1 (fr)
CN (1) CN104725397B (fr)
AP (1) AP2014008127A0 (fr)
AR (1) AR098906A1 (fr)
AU (1) AU2014274644B2 (fr)
BR (1) BR102014032336B1 (fr)
CA (1) CA2875226C (fr)
CL (1) CL2014003444A1 (fr)
CO (1) CO7210068A1 (fr)
CR (1) CR20140569A (fr)
CU (1) CU24309B1 (fr)
CY (1) CY1118058T1 (fr)
DK (1) DK2886545T3 (fr)
DO (1) DOP2014000282A (fr)
EA (1) EA029601B1 (fr)
ES (1) ES2594377T3 (fr)
FR (1) FR3015483B1 (fr)
GE (1) GEP201706619B (fr)
GT (1) GT201400297A (fr)
HK (2) HK1209750A1 (fr)
HR (1) HRP20161203T8 (fr)
HU (1) HUE029654T2 (fr)
IL (1) IL236143A (fr)
JO (1) JO3193B1 (fr)
LT (1) LT2886545T (fr)
MD (1) MD4516C1 (fr)
ME (1) ME02521B (fr)
MX (1) MX351581B (fr)
MY (1) MY185221A (fr)
NI (1) NI201400150A (fr)
PE (1) PE20151064A1 (fr)
PH (1) PH12014000375B1 (fr)
PL (1) PL2886545T3 (fr)
PT (1) PT2886545T (fr)
RS (1) RS55213B1 (fr)
RU (1) RU2605403C2 (fr)
SA (1) SA114360144B1 (fr)
SG (1) SG10201408563UA (fr)
SI (1) SI2886545T1 (fr)
TN (1) TN2014000516A1 (fr)
TW (1) TWI508969B (fr)
UA (1) UA120341C2 (fr)
UY (1) UY35915A (fr)
WO (1) WO2015097123A1 (fr)
ZA (1) ZA201409365B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3212202B1 (fr) 2014-10-29 2020-05-06 The Walter and Eliza Hall Institute of Medical Research Inhibiteurs de mcl-1 pour le traitement des maladies causées par le neovascularisation pathologique
US20180179210A1 (en) * 2015-05-27 2018-06-28 Pharmascience Inc. Inhibitors of the TEC Kinase Enzyme Family
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2017197055A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
WO2017197046A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2018015526A1 (fr) 2016-07-22 2018-01-25 Les Laboratoires Servier Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées
SG11201900402UA (en) * 2016-07-22 2019-02-27 Servier Lab Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
HUE059448T2 (hu) * 2016-10-28 2022-11-28 Servier Lab Liposzómás készítmény, rák kezelésében való alkalmazásra
EP3567043B1 (fr) * 2017-01-05 2023-12-06 Henan Genuine Biotech Co., Ltd. Dérivés du acide propanoïque 2-[[5-[(4-hydroxy-3-chloro-2-méthyl)-phényl]-thiéno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-méthoxybenzene) en tant qu'inhibiteurs mcl-1 et bcl-2 pour le traitement du cancer
JOP20190159B1 (ar) * 2017-01-06 2023-09-17 Servier Lab توليفة من مثبط mcl-1 ومركب تاكسان، استخداماتها وتركيباتها الصيدلانية
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
EA039621B1 (ru) * 2017-06-09 2022-02-17 Ле Лаборатуар Сервье Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
BR112019026959A2 (pt) * 2017-06-22 2020-07-07 Les Laboratoires Servier combinação de um inibidor de mcl-1 e um tratamento com padrão de atendimento para cânceres hematológicos, seus usos e composições farmacêuticas
GB201712282D0 (en) * 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
CN111818916A (zh) * 2017-08-15 2020-10-23 艾伯维公司 大环mcl-1抑制剂和使用方法
BR112020003180A2 (pt) * 2017-08-15 2020-09-15 AbbVie Deutschland GmbH & Co. KG inibidores macrocíclicos de mcl-1 e métodos de uso
JP2020531436A (ja) * 2017-08-15 2020-11-05 アッヴィ・インコーポレイテッド 大環状ｍｃｌ−１阻害剤及び使用の方法
CN107573360B (zh) * 2017-10-27 2019-08-09 都创(上海)医药科技有限公司 一种多靶点小分子化合物s63845的制备方法
CN111372936B (zh) * 2017-11-23 2022-12-02 北京赛林泰医药技术有限公司 Mcl-1选择性抑制剂及其制备和用途
CN108424417B (zh) * 2017-12-21 2019-09-20 河南真实生物科技有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
CN110964034B (zh) * 2018-09-29 2022-04-12 江苏恒瑞医药股份有限公司 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
AR116635A1 (es) * 2018-10-15 2021-05-26 Servier Lab Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
CN111187277B (zh) * 2018-11-14 2022-04-12 江苏恒瑞医药股份有限公司 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
TW202038960A (zh) 2018-11-14 2020-11-01 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
US20220017533A1 (en) * 2018-12-06 2022-01-20 Les Laboratoires Servier Crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
JP2022532918A (ja) * 2019-05-20 2022-07-20 ノバルティス アーゲー Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
TW202114682A (zh) 2019-06-17 2021-04-16 法商施維雅藥廠 Mcl-1抑制劑與乳癌標準療法之組合，其用途及醫藥組合物
AR119493A1 (es) 2019-07-29 2021-12-22 Servier Lab Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
AR119494A1 (es) 2019-07-29 2021-12-22 Servier Lab DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS
JP2022551083A (ja) * 2019-10-03 2022-12-07 カリフォルニア インスティチュート オブ テクノロジー Ｍｃｌ１インヒビター及びその使用
CN113024577B (zh) * 2019-12-09 2023-06-30 首药控股(北京)股份有限公司 一种抗凋亡蛋白选择性抑制剂的制备方法
CN113024578A (zh) * 2019-12-09 2021-06-25 首药控股(北京)有限公司 一种mcl1选择性抑制剂的多晶型物及其制备方法
WO2022090443A1 (fr) 2020-10-30 2022-05-05 Les Laboratoires Servier Administration et posologie pour une combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1
CN116761635A (zh) 2020-11-24 2023-09-15 诺华股份有限公司 Bcl-xl抑制剂抗体药物缀合物及其使用方法
JP2023553808A (ja) 2020-11-24 2023-12-26 ノバルティス アーゲー Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
UY39609A (es) 2021-01-12 2022-08-31 Servier Lab Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos
WO2022169780A1 (fr) 2021-02-02 2022-08-11 Les Laboratoires Servier Composés bcl-xl protac sélectifs et procédés d'utilisation
WO2022216946A1 (fr) * 2021-04-07 2022-10-13 California Institute Of Technology Inhibiteurs de mcl1 et leurs utilisations
WO2022255888A1 (fr) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Dégradation de protéine ciblée à l'aide de composés bifonctionnels qui se lient à l'ubiquitine ligase et à la protéine mcl-1 cible
WO2022261310A1 (fr) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Inhibiteurs de mcl-1 en combinaison avec des conjugués anti-corps-médicament
CA3222269A1 (fr) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Inhibiteurs de mcl-1 en combinaison avec des agents anticancereux
WO2023225320A1 (fr) 2022-05-20 2023-11-23 Novartis Ag Conjugués anticorps-médicament inhibiteurs de bcl-xl et méthodes d'utilisation associées
WO2023225336A1 (fr) 2022-05-20 2023-11-23 Novartis Ag Conjugués anticorps-médicament inhibiteurs de met bcl-xl et leurs procédés d'utilisation
WO2023225359A1 (fr) 2022-05-20 2023-11-23 Novartis Ag Conjugués anticorps-médicament de composés anti-cancéreux et procédés d'utilisation
WO2024008941A1 (fr) 2022-07-08 2024-01-11 Les Laboratoires Servier Nouveaux dérivés de spirocyclohexane, compositions pharmaceutiques les contenant et leurs utilisations comme inhibiteurs anti-apoptotiques

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008726A1 (de) * 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
MXPA05013549A (es) * 2003-06-11 2006-04-05 Xention Discovery Ltd Derivados de tienopirimidina como inhibidores del canal de potasio.
US20050165029A1 (en) 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
US20050288906A1 (en) 2004-06-29 2005-12-29 Drennen James K Iii Spectroscopic pharmacy verification and inspection system
JP2008505084A (ja) 2004-06-29 2008-02-21 アムゲン インコーポレイティッド フラノピリミジン
SG156650A1 (en) * 2004-07-16 2009-11-26 Sunesis Pharmaceuticals Inc Thienopyrimidines useful as aurora kinase inhibitors
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
US7576080B2 (en) * 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
WO2007046809A1 (fr) * 2005-10-21 2007-04-26 Dow Agrosciences Llc Composes de thieno-pyrimidine a activite fongicide
ZA200904531B (en) * 2006-12-07 2010-09-29 Hoffmann La Roche Phosphoinositide 3-kinase inhibitor compounds and methods of use
DE102007027800A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
MX2010004260A (es) * 2007-10-16 2010-04-30 Wyeth Llc Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y pi3 cinasa.
WO2010054285A2 (fr) 2008-11-10 2010-05-14 National Health Research Institutes Composés de pyrimidine bicycliques et tricycliques condensés à titre d'inhibiteurs de tyrosine kinase
BR112012033253A2 (pt) * 2010-06-23 2016-11-22 Hanmi Science Co Ltd novos derivados de pirimidina fundidos para inibição da atividade de tirosina quinase
WO2012044993A1 (fr) * 2010-09-30 2012-04-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Composés, compositions pharmaceutiques, et procédés de traitement ou de prévention de maladies ou de troubles neurodégénératifs
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PH12014000375A1 (en) 2016-06-13
US20190201404A1 (en) 2019-07-04
HK1211583A1 (en) 2016-05-27
DOP2014000282A (es) 2016-06-30
EA201401292A3 (ru) 2015-08-31
UY35915A (es) 2015-07-31
US9670227B2 (en) 2017-06-06
MX351581B (es) 2017-10-20
EP2886545A1 (fr) 2015-06-24
ME02521B (fr) 2017-02-20
LT2886545T (lt) 2016-09-26
AR098906A1 (es) 2016-06-22
CU20140143A7 (es) 2016-07-29
TN2014000516A1 (en) 2016-03-30
MD4516B1 (ro) 2017-09-30
HRP20161203T1 (hr) 2016-11-04
SI2886545T1 (sl) 2016-10-28
HRP20161203T8 (hr) 2016-12-30
MD4516C1 (ro) 2018-04-30
AU2014274644A1 (en) 2015-07-09
ES2594377T3 (es) 2016-12-19
EP2886545B1 (fr) 2016-06-29
CU24309B1 (es) 2018-01-10
US10278972B2 (en) 2019-05-07
CL2014003444A1 (es) 2015-10-23
PH12014000375B1 (en) 2016-06-13
SA114360144B1 (ar) 2015-10-08
CA2875226C (fr) 2018-03-13
MD20140137A2 (ro) 2015-06-30
BR102014032336B1 (pt) 2020-10-20
CY1118058T1 (el) 2017-06-28
TWI508969B (zh) 2015-11-21
JP2015129120A (ja) 2015-07-16
CN104725397A (zh) 2015-06-24
GT201400297A (es) 2017-08-24
AU2014274644B2 (en) 2019-11-14
PT2886545T (pt) 2016-08-25
ZA201409365B (en) 2021-07-28
CN104725397B (zh) 2017-11-28
IL236143A (en) 2017-02-28
RU2014151850A (ru) 2016-07-20
EA029601B1 (ru) 2018-04-30
CO7210068A1 (es) 2015-03-09
NZ702851A (en) 2016-05-27
CA2875226A1 (fr) 2015-06-23
SG10201408563UA (en) 2015-07-30
DK2886545T3 (en) 2016-09-19
TW201529583A (zh) 2015-08-01
WO2015097123A1 (fr) 2015-07-02
MX2014015854A (es) 2015-07-22
PL2886545T3 (pl) 2017-03-31
GEP201706619B (en) 2017-02-10
BR102014032336A2 (pt) 2016-06-07
CR20140569A (es) 2016-07-01
US20150175623A1 (en) 2015-06-25
US20170216293A1 (en) 2017-08-03
KR101636401B1 (ko) 2016-07-05
FR3015483A1 (fr) 2015-06-26
PE20151064A1 (es) 2015-08-08
EA201401292A2 (ru) 2015-06-30
RS55213B1 (sr) 2017-02-28
JP5922215B2 (ja) 2016-05-24
HUE029654T2 (en) 2017-02-28
NI201400150A (es) 2015-06-05
MY185221A (en) 2021-04-30
UA120341C2 (uk) 2019-11-25
KR20150073874A (ko) 2015-07-01
AP2014008127A0 (en) 2014-12-31
JO3193B1 (ar) 2018-03-08
HK1209750A1 (en) 2016-04-08
RU2605403C2 (ru) 2016-12-20

Similar Documents

Publication Publication Date Title
FR3015483B1 (fr) Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008979B1 (fr) Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2986002B1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3052452B1 (fr) Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
LT2829539T (lt) Nauji pirolo dariniai, jų gamybos būdas ir juos turinčios farmacinės kompozicijos
CL2014003165A1 (es) Proceso mejorado para la preparación de treprostinil y derivados del mismo.
EA202190774A3 (ru) Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения
FR2943342B1 (fr) Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR3030536B1 (fr) Organopolysiloxanes et leur procede de preparation
PT3069720T (pt) Composição farmacológica que contém derivados de glutarimida, e a aplicação da mesma no tratamento de doenças eosinofílicas
IL246406A0 (en) History of imidazopyrazinone, their preparation and pharmaceutical preparations containing them
IL243227A0 (en) History of diaminocyclopentane carboxamide, their preparation and pharmaceutical preparations containing them
MA50450A (fr) Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3078659A4 (fr) Dérivé de 3-furyl-2-cyano-2-acrylamide, son procédé de préparation, composition pharmaceutique et son utilisation
IL239873B (en) The history of piperidinylcarbazole, their preparation and pharmaceutical preparations containing them
FR2986527B1 (fr) Procede de preparation de phosphines tertiaires et de derives de celles-ci.
FR2948372B1 (fr) Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2972454B1 (fr) Nouveaux derives dihydro-oxazolobenzodiazepinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2964969B1 (fr) Nouveaux derives dihydrobenzoxathiazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046793B1 (fr) Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3011839B1 (fr) Procede de preparation de derives d'acetamidophenyle
FR3052451B1 (fr) Nouveaux derives de piperidinyle hetero(aryl)-substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3026009B1 (fr) Nanocapsules lipidiques, compositions pharmaceutiques, procede de preparation, et utilisations correspondants

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

ST Notification of lapse

Effective date: 20180831